NeuroVive Pharmaceutical AB ROCE
Was ist das ROCE von NeuroVive Pharmaceutical AB?
ROCE von NeuroVive Pharmaceutical AB ist -66.00%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Miscellaneous Sektor auf LSE im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit roce ähnlich NeuroVive Pharmaceutical AB
- Revance Therapeutics Inc hat ROCE von -66.25%
- Castlecap Capital hat ROCE von -66.21%
- CASI Pharmaceuticals Inc hat ROCE von -66.16%
- Argent Minerals hat ROCE von -66.09%
- 17 Education & Technology hat ROCE von -66.03%
- Bed, Bath & Beyond hat ROCE von -66.01%
- NeuroVive Pharmaceutical AB hat ROCE von -66.00%
- Aurum Resources Ltd hat ROCE von -65.87%
- Allot Ltd hat ROCE von -65.75%
- Eledon Pharmaceuticals hat ROCE von -65.68%
- Arrowhead Pharmaceuticals hat ROCE von -65.68%
- Stereotaxis hat ROCE von -65.63%
- UroGen Pharma hat ROCE von -65.59%